COPD患者从沙美特罗/氟替卡松直接转换为茚达特罗/格隆溴铵的疗效与安全性:FLASH随机对照试验
FLASH为12周多中心双盲随机对照试验,纳入502例中度至重度COPD且过去一年加重不超过一次、已用SFC至少3个月的患者,比较继续SFC 50/500 μg每日两次与直接转换为IND/GLY 110/50 μg每日一次。结果显示转换组第12周给药前谷值FEV1优于SFC组(差值45 mL,P=0.028),FVC亦显著改善(差值102 mL,P=0.002),安全性相似。
要点
- 直接转换至IND/GLY较继续SFC改善第12周给药前谷值FEV1(差值45 mL,P=0.028)。
- 转换组给药前谷值FVC显著改善(差值102 mL,P=0.002)。
- 两组安全性相似,未发现新的安全性信号。
核心结论
- 在過去一年加重不超过一次的中度至重度COPD患者中,从SFC直接转换为IND/GLY可改善给药前谷值FEV1和FVC,且未发现新的安全性信号。
研究设计与样本
- 12周、多中心、双盲随机对照试验,502例患者按1:1随机分配至IND/GLY或SFC。
- 纳入中度至重度COPD、过去一年加重不超过一次、已接受SFC至少3个月的患者。
- 干预为继续SFC 50/500 μg每日两次或直接转换为IND/GLY 110/50 μg每日一次,无洗脱期。
主要发现
- 第12周给药前谷值FEV1:IND/GLY优于SFC,治疗差值45 mL,P=0.028。
- 给药前谷值FVC:IND/GLY显著改善,差值102 mL,P=0.002。
- TDI数值改善但未达统计学显著(差值0.46,P=0.063)。
- 救援药物使用和CAT评分两组相当,安全性特征相似。
临床怎么用
- 对于已使用SFC至少3个月、过去一年加重不超过一次的中度至重度COPD患者,可考虑直接转换为IND/GLY而无需洗脱期,以改善肺功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Combination long-acting β2 -agonist/long-acting muscarinic antagonist (LABA/LAMA) has demonstrated superior clinical outcomes over LABA/inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD) patients; however, data from blinded randomized controlled trials on direct switching from LABA/ICS to LABA/LAMA are lacking. FLASH (Assessment of switching salmeterol/Fluticasone to indacateroL/glycopyrronium in A Symptomatic COPD patient coHort) investigated if direct switch, without a washout period, from salmeterol/fluticasone (SFC) to indacaterol/glycopyrronium (IND/GLY) in COPD patients improves lung function and is well tolerated. METHODS: In this 12-week, multicentre, double-blind study, patients with moderate-to-severe COPD and up to one exacerbation in previous year, receiving SFC for ≥3 months, were randomized to continue SFC 50/500 μg twice daily (bd) or switch to IND/GLY 110/50 μg once daily (od). Primary endpoint was pre-dose trough forced expiratory volume in 1 s (FEV1 ) at Week 12. RESULTS: In total, 502 patients were randomized (1:1) to IND/GLY or SFC. Patients switched to IND/GLY demonstrated superior lung function (pre-dose trough FEV1 ) versus SFC at Week 12 (treatment difference (Δ) = 45 mL; P = 0.028). IND/GLY provided significant improvements in pre-dose trough forced vital capacity (FVC; Δ = 102 mL; P = 0.002) and numerical improvements in transition dyspnoea index (TDI; Δ = 0.46; P = 0.063). Rescue medication use and COPD assessment test (CAT) scores were comparable between groups. Both treatments had similar safety profiles. CONCLUSION: FLASH demonstrated that a direct switch to IND/GLY from SFC improved pre-dose FEV1 and FVC in COPD patients with up to one exacerbation in the previous year. No new safety signals were identified.
引用
- Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirology. 2018. PMID: 30074294. doi:10.1111/resp.13374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。